Kintor Pharmaceutical Ltd (9939)

Currency in HKD
1.31
-0.05(-3.66%)
Closed·
Advertisement
9939 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.271.33
52 wk Range
1.214.70
Key Statistics
Bid/Ask
1.31 / 1.31
Prev. Close
1.37
Open
1.33
Day's Range
1.27-1.33
52 wk Range
1.21-4.7
Volume
895.5K
Average Volume (3m)
904.46K
1-Year Change
-33.1633%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
9939 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Kintor Pharmaceutical Ltd News & Analysis

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Earnings

Latest Release
19/08/2026
EPS / Forecast
-0.15 / --
Revenue / Forecast
52.04M / --
EPS Revisions
Last 90 days

Compare 9939 to Peers and Sector

Metrics to compare
9939
Peers
Sector
Relationship
P/E Ratio
−2.9x−9.7x−0.2x
PEG Ratio
0.710.040.00
Price/Book
5.0x4.0x2.6x
Price / LTM Sales
7.0x9.3x2.6x
Upside (Analyst Target)
-97.4%76.9%
Fair Value Upside
Unlock17.8%14.9%Unlock

Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris that is in phase II clinical trial. The company is also developing ALK-1 Antibody (GT90001), an anti-angiogenesis inhibitor and targets a new biological target activin receptor-like kinase-1 globally to treat metastatic hepatocellular carcinoma, a common type of liver cancer, and a variety of solid tumours that is in phase I and II clinical trial; GT1708F (Hedgehog/SMO Inhibitor), an inhibitor of the hedgehog signal transduction pathway to treat idiopathic pulmonary fibrosis, and blood cancer that is in phase I clinical trial; and GT0486, an inhibitor of the PI3K/mTOR signalling pathway and a second generation mTOR inhibitor for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC) that is in phase I clinical trial. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People’s Republic of China.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
28.50K0.01%37.34K
Other Institutional Investors
92.62M18.76%121.33M
Public Companies & Retail Investors
401.16M81.24%525.52M
Total
493.81M100.00%646.89M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
China-Singapore Suzhou Industrial Park Ventures Co., Ltd.6.17%30,487,50039,939
Zhuhai Gree Financial Investment Management Co., Ltd.5.04%24,873,50032,584

FAQ

What Is the Kintor Pharma (Hong Kong: 9939) Share Price Today?

The Kintor Pharma stock price today is 1.31 HKD.

What Stock Exchange Does Kintor Pharma (9939) Trade On?

Kintor Pharma is listed and trades on the Hong Kong Stock Exchange.

What Is the Ticker (Stock Symbol) for Kintor Pharma?

The stock symbol (also called a 'ticker') for Kintor Pharma is "9939."

What Is the Current Kintor Pharma Market Capitalisation?

As of today, Kintor Pharma (Hong Kong: 9939) market cap is 646.89M HKD.

What Is Kintor Pharma's (9939) Earnings Per Share (TTM)?

The Kintor Pharma EPS is currently -0.46 (Trailing Twelve Months).

Is 9939 a Buy or Sell From a Technical Analyst Perspective?

Based on today's Kintor Pharma moving averages and other technical indicators, the daily buy/sell signal for 9939 stock is Strong Sell.

How Many Times Has Kintor Pharma Stock Split?

Kintor Pharma has split 0 times. (See the 9939 stock split history page for full effective split date and price information.)

How Many Employees Does Kintor Pharma Have?

Kintor Pharma has 122 employees, based on their latest Companies House report.

What is the current trading status of Kintor Pharma (Hong Kong: 9939)?

As of 21/11/2026, Kintor Pharma (9939) is trading at a share price of 1.31 HKD, with a previous close of 1.37 HKD. The stock has fluctuated within a day range of 1.27 HKD to 1.33 HKD, while its 52-week range spans from 1.21 HKD to 4.70 HKD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.